A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: A Children's Oncology Group study†

Neuro-Oncology

Volumn 17, Issue 8, 2015, Pages 1132-1138

  Chintagumpala, Murali ^a   Eckel, Sandrah P ^b   Krailo, Mark ^b   Morris, Michael ^c   Adesina, Adekunle ^a   Packer, Roger ^d   Lau, Ching ^a   Gajjar, Amar ^e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Chemotherapy; Low grade glioma; Temozolomide

Indexed keywords

CARBOPLATIN; TEMOZOLOMIDE; VINCRISTINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DACARBAZINE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; GLIOMA; HUMAN; HYPOKALEMIA; HYPONATREMIA; ILEUS; INFECTION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PILOT STUDY; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; ANALOGS AND DERIVATIVES; CHILD; COMBINATION DRUG THERAPY; INDUCTION CHEMOTHERAPY; INFANT; KAPLAN MEIER METHOD; MORTALITY; PRESCHOOL CHILD;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DRUG THERAPY, COMBINATION; FEMALE; GLIOMA; HUMANS; INDUCTION CHEMOTHERAPY; INFANT; KAPLAN-MEIER ESTIMATE; MALE; PILOT PROJECTS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84943257572     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov057     Document Type: Article

References (31)

1. Pollack IF. Brain tumors in children. N Engl J Med. 1994;331(22): 1500-1507.
2. Gajjar A, Sanford RA, Heideman R, et al. Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital. J Clin Oncol. 1997;15(8):2792-2799.
3. Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993;11(5):850-856.
4. Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86(5):747-754.
5. Petronio J, Edwards MS, Prados M, et al. Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. J Neurosurg. 1991;74(5):701-708.
6. Prados MD, Edwards MS, Rabbitt J, et al. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol. 1997;32(3):235-241.
7. Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012;30(12):1358-1363.
8. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer. 2009;52(7):791-795.
9. Massimino M, Spreafico F, Cefalo G, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol. 2002;20(20):4209-4216.
10. Massimino M, Spreafico F, Riva D, et al. A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neurooncol. 2010;100(1):65-71.
11. Laithier V, Grill J, Le Deley MC, et al. Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy-results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol. 2003;21(24):4572-4578.
12. Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol. 2012;30(21):2641-2647. doi:10.1200/JCO.2011. 36.6054. Epub 2012 Jun 4.
13. Khaw SL, Coleman LT, Downie PA, et al. Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer. 2007;49(6):808-811.
14. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007;110(7):1542-1550.
15. Lafay-Cousin L, Sung L, Carret AS, et al. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma. Cancer. 2008;112(4):892-899.
16. Chang SM, Fryberger S, Crouse V, et al. Carboplatin hypersensitivity in children. Cancer. 1995;75(5):1171-1175.
17. Yu DY, Dahl GVH, Shames RS, et al. Weekly dosing of carboplatin increases risk of allergy in children. J Pediatr Hematol Oncol. 2001;23(6):349-352.
18. Schiavetti A, Varrasso G, Maurizi P, et al. Hypersensitivity to carboplatin in children. Med Pediatr Oncol. 1999;32(3):183-185.
19. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons; 2002.
20. Gnekow AK, Falkenstein F, von Hornstein S, et al. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol. 2012;14(10): 1265-1284.
21. Yu J, Deshmukh H, Gutmann RJ, et al. Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology. 2009;73(19):1526-1531. doi:10.1212/WNL.0b013e 3181c0664a. Epub 2009 Sep 30.
22. Jones DT, Kocialkowski S, Liu L, et al. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene. 2009;28(20):2119-2123.
23. Pfister S, Janzarik WG, Remke M, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008;118(5):1739-1749.
24. Zhang J, Wu G, Miller CP, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013;45(6):602-612.
25. Cin H, Meyer C, Herr R, et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. 2011;121(6):763-774.
26. Sievert AJ, Jackson EM, Gai X, et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol. 2009;19(3):449-458.
27. Bar EE, Lin A, Tihan T, et al. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol. 2008;67(9):878-887.
28. Jacob K, Albrecht S, Sollier C, et al. Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer. 2009;101(4):722-733.
29. Lin A, Rodriguez FJ, Karajannis MA, et al. BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol. 2012;71(1):66-72.
30. Forshew T, Tatevossian RG, Lawson AR, et al. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol. 2009;218(2):172-181.
31. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1, 320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):397-405.